NOV (NOV)
(Real Time Quote from BATS)
$18.84 USD
+0.30 (1.62%)
Updated May 6, 2024 01:45 PM ET
3-Hold of 5 3
A Value F Growth F Momentum C VGM
Price, Consensus and EPS Surprise
NOV 18.84 +0.30(1.62%)
Will NOV be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for NOV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NOV
NOV Q1 Earnings Surpass Estimates, Revenues Increase Y/Y
Nov Inc. (NOV) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
NOV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nov Inc. (NOV) Tops Q1 Earnings and Revenue Estimates
Trane Technologies (TT) Earnings Expected to Grow: Should You Buy?
Earnings Preview: Nov Inc. (NOV) Q1 Earnings Expected to Decline
Other News for NOV
Piper Sandler Gives a Hold Rating to NOV (NOV)
Novatti Group’s 100K Options Expire Unexercised
NOV Inc. stock underperforms Friday when compared to competitors
Buy Rating Affirmed for Novo Nordisk on Strong Product Performance and Market Position
NOV Inc. stock outperforms competitors on strong trading day